Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01070979 · ClinicalTrials.gov registry record · Phase 3
Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT01070979: Completed Phase 3 study, sponsored by Warner Chilcott.
NCT01070979 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 249 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01070979, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
Multicenter, double-blind, controlled, parallel group, randomized study to compare the clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine estrogen tablets, each administered orally, once daily, to postmenopausal women.
Primary Outcome
Severity of hot flush definitions: mild - sensation of heat without perspiration, moderate - sensation of heat with perspiration, able to continue activity, severe - sensation of heat with perspiration, causing the subject to stop activity or awaken from sleep
Interventions
- DRUG Estradiol
- DRUG Estradiol acetate
- DRUG Conjugated equine estrogens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2003-02 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
What the finished NCT01070979 record still lists
NCT01070979 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 3 interventions - of which Estradiol is the first listed.
NCT01070979 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01070979 about?
NCT01070979 is a clinical study titled "Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.". Multicenter, double-blind, controlled, parallel group, randomized study to compare the clinical benefit of Estradiol acetate tablets, estradiol tablets and conjugated equine estrogen tablets, each administered orally, once daily, to postmenopausal women.
What is the current status of trial NCT01070979?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2003-02. Estimated completion is 2003-09.
What interventions are being tested in trial NCT01070979?
The interventions under investigation include: Estradiol (DRUG), Estradiol acetate (DRUG), Conjugated equine estrogens (DRUG).
Who is sponsoring clinical trial NCT01070979?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01070979's enrollment target sits among peer trials
249 1266th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia